Insider Selling: Teleflex Incorporated (NYSE:TFX) Director Sells $77,270.00 in Stock

Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $386.35, for a total transaction of $77,270.00. Following the transaction, the director now owns 1,321 shares in the company, valued at approximately $510,368.35. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

TFX opened at $385.17 on Friday. The company has a quick ratio of 2.38, a current ratio of 3.60 and a debt-to-equity ratio of 0.79. The stock’s 50 day moving average price is $367.75 and its two-hundred day moving average price is $350.53. The firm has a market capitalization of $17.88 billion, a P/E ratio of 32.95, a price-to-earnings-growth ratio of 2.93 and a beta of 1.01. Teleflex Incorporated has a 12-month low of $221.27 and a 12-month high of $405.07.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.68. Teleflex had a return on equity of 18.96% and a net margin of 21.12%. The company had revenue of $567.00 million during the quarter, compared to analysts’ expectations of $537.85 million. During the same period in the prior year, the business earned $2.66 earnings per share. Teleflex’s revenue for the quarter was down 13.1% compared to the same quarter last year. As a group, analysts anticipate that Teleflex Incorporated will post 10.09 earnings per share for the current year.

A number of brokerages recently issued reports on TFX. Wells Fargo & Co upped their price objective on shares of Teleflex from $365.00 to $375.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Piper Sandler decreased their price target on Teleflex from $425.00 to $375.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. JMP Securities lowered their price objective on Teleflex from $395.00 to $385.00 and set a “market outperform” rating on the stock in a report on Friday, May 1st. UBS Group reduced their target price on Teleflex from $440.00 to $410.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Raymond James increased their price target on Teleflex from $360.00 to $400.00 and gave the company a “strong-buy” rating in a report on Friday, May 1st. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teleflex presently has a consensus rating of “Buy” and an average target price of $383.40.

A number of hedge funds and other institutional investors have recently bought and sold shares of TFX. Winslow Evans & Crocker Inc. increased its holdings in shares of Teleflex by 46.9% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 94 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 30 shares during the period. Ellevest Inc. grew its position in Teleflex by 102.1% during the first quarter. Ellevest Inc. now owns 95 shares of the medical technology company’s stock worth $28,000 after buying an additional 48 shares in the last quarter. Contravisory Investment Management Inc. increased its stake in Teleflex by 816.7% during the first quarter. Contravisory Investment Management Inc. now owns 110 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 98 shares during the period. Signaturefd LLC raised its holdings in Teleflex by 431.8% in the 1st quarter. Signaturefd LLC now owns 117 shares of the medical technology company’s stock valued at $34,000 after acquiring an additional 95 shares in the last quarter. Finally, Financial Management Professionals Inc. bought a new stake in shares of Teleflex in the 2nd quarter worth approximately $71,000. Institutional investors own 91.20% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Further Reading: How to Invest in Growth Stocks

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.